# US 2025/0154151 A1 · Pyrimidoheterocyclic compounds and application thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0154151 A1
- Document ID: US20250154151A1
- Status: Published application
- Kind: A1
- Application number: 18/923,767
- Filed: 2024-10-23
- Published: 2025-05-15
- Earliest claimed: 2020-03-12
- Assignees: D3 Bio (Wuxi) Co., Ltd.
- Applicants: D3 Bio (Wuxi) Co., Ltd.
- Inventors: Yang ZHANG; Wentao WU; Jing ZHANG; Jikui SUN; Yangyang XU; Zhijian CHEN; John Fenyu JIN; Shuhui CHEN
- Web page: https://patentgrep.com/patent/US20250154151A1

## CPC

- A61P 35/00: Antineoplastic agents
- C07D 471/04: Ortho-condensed systems
- C07D 403/04: directly linked by a ring-member-to-ring-member bond
- C07D 491/052: the oxygen-containing ring being six-membered
- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

A class of pyrimidoheterocyclic compounds, and specifically disclosed is a compound represented by formula (III) or a pharmaceutically acceptable salt thereof.

## Claims

### Claim 1

A compound represented by formula (III) or a pharmaceutically acceptable salt thereof,
wherein
T1 is selected from O and N;
R1 is selected from C6-10 aryl and 5- to 10-membered heteroaryl, wherein the C6-10 aryl and 5- to 10-membered heteroaryl are optionally substituted with 1, 2, 3, 4 or 5 Ra;
when T1 is O, R2 is not present;
when T1 is N, R2 is selected from H, C1-3 alkyl, —C(═O)—C1-3 alkyl and —S(═O)2—C1-3 alkyl, wherein the C1-3 alkyl, —C(═O)—C1-3 alkyl and —S(═O)2—C1-3 alkyl are optionally substituted with 1, 2 or 3 Rb;
R3 is C1-3 alkyl, wherein the C1-3 alkyl is optionally substituted with 1, 2 or 3 Rc;
R4 is selected from H and C1-3 alkyl, wherein the C1-3 alkyl is optionally substituted with 1, 2 or 3 Rd;
R5, R6 and R7 are each independently selected from H, F, Cl, Br, I, and C1-3 alkyl, wherein the C1-3 alkyl is optionally substituted with 1, 2 or 3 F;
R8 is selected from H and CH3;
Ra is each independently selected from F, Cl, Br, I, OH, NH2, CN, C1-3 alkyl, C1-3 alkoxy, C2-3 alkynyl and C2-3 alkenyl, wherein the C1-3 alkyl, C1-3 alkoxy, C2-3 alkynyl and C2-3 alkenyl are optionally substituted with 1, 2 or 3 F;
Rb is each independently selected from F, Cl, Br, I, OH and NH2;
Rc is each independently selected from 4- to 8-membered heterocycloalkyl, wherein the 4- to 8-membered heterocycloalkyl is optionally substituted with 1, 2 or 3 R;
Rd is each independently selected from F, Cl, Br, I, OH, NH2 and CN;
R is each independently selected from H, F, Cl, Br, OH, CN, C1-3 alkyl, C1-3 alkoxy and —C1-3 alkyl-O—C(═O)—C1-3 alkylamino;
provided that when R1 is naphthyl, the naphthyl is optionally substituted with F, Cl, Br, OH, NH2, CF3, CH2CH3 and —C≡CH, and R5, R6 and R7 are each independently H.

### Claim 2 (depends on 1)

The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein Ra is each independently selected from F, Cl, Br, I, OH, NH2, CN, CH3, CH2CH3, OCH3, OCH2CH3, —CH═CH2, —CH2—CH═CH2 and —C≡CH, wherein the CH3, CH2CH3, OCH3, OCH2CH3, —CH═CH2, —CH2—CH═CH2 and —C≡CH are optionally substituted with 1, 2 or 3 F.

### Claim 3 (depends on 2)

The compound according to claim 2, or a pharmaceutically acceptable salt thereof, wherein Ra is each independently selected from F, OH, NH2, CH3, CF3, CH2CH3 and —C≡CH.

### Claim 4 (depends on 1)

The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R1 is selected from phenyl, naphthyl, indolyl and indazolyl, wherein the phenyl, naphthyl, indolyl and indazolyl are optionally substituted with 1, 2 or 3 Ra.

### Claim 5 (depends on 4)

The compound according to claim 4, or a pharmaceutically acceptable salt thereof, wherein R1 is selected from

### Claim 6 (depends on 1)

The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R2 is selected from H, CH3, CH2CH3 and CH(CH3)2, wherein the CH3, CH2CH3 and CH(CH3)2 are optionally substituted with 1, 2 or 3 Rb.

### Claim 7 (depends on 6)

The compound according to claim 6, or a pharmaceutically acceptable salt thereof, wherein R2 is selected from H and CH3.

### Claim 8 (depends on 1)

The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R is each independently selected from H, F, Cl, Br, OH, CN, CH3, CH2CH3, CH2CF3, OCH3, OCF3 and

### Claim 9 (depends on 1)

The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein Re is selected from tetrahydropyrrolyl and hexahydro-1H-pyrrolizinyl, wherein the tetrahydropyrrolyl and hexahydro-1H-pyrrolizinyl are optionally substituted with 1, 2 or 3 R.

### Claim 10 (depends on 9)

The compound according to claim 9, or a pharmaceutically acceptable salt thereof, wherein Re is selected from

### Claim 11 (depends on 1)

The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein Re is selected from

### Claim 12 (depends on 1)

The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R3 is CH3, wherein the CH3 is optionally substituted with 1, 2 or 3 Rc.

### Claim 13 (depends on 12)

The compound according to claim 12, or a pharmaceutically acceptable salt thereof, wherein R3 is selected from

### Claim 14 (depends on 1)

The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R3 is selected from

### Claim 15 (depends on 1)

The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R4 is selected from H and CH3, wherein the CH3 is optionally substituted with 1, 2 or 3 Rd.

### Claim 16 (depends on 15)

The compound according to claim 15, or a pharmaceutically acceptable salt thereof, wherein R4 is selected from H, CH3 and CH2CN.

### Claim 17 (depends on 1)

The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is selected from
wherein
R1 is selected from C6-10 aryl and 5- to 10-membered heteroaryl, wherein the C6-10 aryl and 5- to 10-membered heteroaryl are optionally substituted with 1, 2, 3, 4 or 5 Ra;
Ra is each independently selected from F, Cl, Br, I, OH, NH2, CN, C1-3 alkyl, C1-3 alkoxy, C2-3 alkynyl and C2-3 alkenyl, wherein the C1-3 alkyl, C1-3 alkoxy, C2-3 alkynyl and C2-3 alkenyl are optionally substituted with 1, 2 or 3 F;
R4 is C1-3 alkyl, wherein the C1-3 alkyl is optionally substituted with 1, 2 or 3 Rd;
Rd is each independently selected from F, Cl, Br, I, OH, NH2 and CN;
R5 is H, F, Cl, Br, I, or C1-3 alkyl, wherein the C1-3 alkyl is optionally substituted with 1, 2 or 3 F;
Rc is 4- to 8-membered heterocycloalkyl, wherein the 4- to 8-membered heterocycloalkyl is optionally substituted with 1, 2 or 3 R;
R is each independently selected from H, F, Cl, Br, OH, CN, C1-3 alkyl, C1-3 alkoxy and —C1-3 alkyl-O—C(═O)—C1-3 alkylamino;
provided that when R1 is naphthyl, the naphthyl is optionally substituted with F, Cl, Br, OH, NH2, CF3, CH2CH3 and —C≡CH, and R5 is H; and
the carbon atom with “*” is a chiral carbon atom, which exists in the form of (R) or (S) single enantiomer or is enriched in one enantiomer.

### Claim 18 (depends on 1)

The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is selected from
wherein
R1 is selected from C6-10 aryl and 5- to 10-membered heteroaryl, wherein the C6-10 aryl and 5- to 10-membered heteroaryl are optionally substituted with 1, 2, 3, 4 or 5 Ra;
Ra is each independently selected from F, Cl, Br, I, OH, NH2, CN, C1-3 alkyl, C1-3 alkoxy, C2-3 alkynyl and C2-3 alkenyl, wherein the C1-3 alkyl, C1-3 alkoxy, C2-3 alkynyl and C2-3 alkenyl are optionally substituted with 1, 2 or 3 F;
R2 is H, C1-3 alkyl, —C(═O)—C1-3 alkyl or —S(═O)2—C1-3 alkyl, wherein the C1-3 alkyl, —C(═O)—C1-3 alkyl, and —S(═O)2—C1-3 alkyl are optionally substituted with 1, 2 or 3 Rb;
Rb is each independently selected from F, Cl, Br, I, OH and NH2;
R4 is selected from H and C1-3 alkyl, wherein the C1-3 alkyl is optionally substituted with 1, 2 or 3 Rd;
R5, R6 and R7 are each independently selected from H, F, Cl, Br, I, and C1-3 alkyl, wherein the C1-3 alkyl is optionally substituted with 1, 2 or 3 F;
R8 is selected from H and CH3;
R is H, F, Cl, Br, OH, CN, C1-3 alkyl, C1-3 alkoxy, or —C1-3 alkyl-O—C(═O)—C1-3 alkylamino;
provided that when R1 is naphthyl, the naphthyl is optionally substituted with F, Cl, Br, OH, NH2, CF3, CH2CH3 and —C≡CH, and R5, R6 and R7 are each independently H.

### Claim 19

A compound represented by the following formula, or a pharmaceutically acceptable salt thereof,

### Claim at position 20

-21. (canceled)

### Claim 22

A method of treating KRAS-related diseases in a subject in need thereof, comprising administering to the subject a compound of represented by formula (III) or a pharmaceutically acceptable salt thereof,
wherein
T1 is selected from O and N;
R1 is selected from C6-10 aryl and 5- to 10-membered heteroaryl, wherein the C6-10 aryl and 5- to 10-membered heteroaryl are optionally substituted with 1, 2, 3, 4 or 5 Ra;
when T1 is O, R2 is not present;
when T1 is N, R2 is selected from H, C1-3 alkyl, —C(═O)—C1-3 alkyl and —S(═O)2—C1-3 alkyl, wherein the C1-3 alkyl, —C(═O)—C1-3 alkyl and —S(═O)2—C1-3 alkyl are optionally substituted with 1, 2 or 3 Rb;
R3 is C1-3 alkyl, wherein the C1-3 alkyl is optionally substituted with 1, 2 or 3 Rc;
R4 is selected from H and C1-3 alkyl, wherein the C1-3 alkyl is optionally substituted with 1, 2 or 3 Rd;
R5, R6 and R7 are each independently selected from H, F, Cl, Br, I, and C1-3 alkyl, wherein the C1-3 alkyl is optionally substituted with 1, 2 or 3 F;
R8 is selected from H and CH3;
Ra is each independently selected from F, Cl, Br, I, OH, NH2, CN, C1-3 alkyl, C1-3 alkoxy, C2-3 alkynyl and C2-3 alkenyl, wherein the C1-3 alkyl, C1-3 alkoxy, C2-3 alkynyl and C2-3 alkenyl are optionally substituted with 1, 2 or 3 F;
Rb is each independently selected from F, Cl, Br, I, OH and NH2;
Rc is each independently selected from 4- to 8-membered heterocycloalkyl, wherein the 4- to 8-membered heterocycloalkyl is optionally substituted with 1, 2 or 3 R;
Rd is each independently selected from F, Cl, Br, I, OH, NH2 and CN;
R is each independently selected from H, F, Cl, Br, OH, CN, C1-3 alkyl, C1-3 alkoxy and —C1-3 alkyl-O—C(═O)—C1-3 alkylamino;
provided that when R1 is naphthyl, the naphthyl is optionally substituted with F, Cl, Br, OH, NH2, CF3, CH2CH3 and —C≡CH, and R5, R6 and R7 are each independently H.
